Journal article
Outcomes of stage II endometrial cancer: The UPMC Hillman Cancer Center experience
Gynecologic oncology, v 147(2), pp 315-319
Nov 2017
PMID: 28866431
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Previous studies of stage II endometrial cancer have included cancers with cervical glandular involvement, a factor no longer associated with risk of recurrence. In order to better assess relapse patterns and the impact of adjuvant therapy, a retrospective analysis was conducted for patients with modern stage II endometrial cancer, defined as cervical stromal invasion.
Patients diagnosed with surgically staged FIGO stage II endometrial cancer at the UPMC Hillman Cancer Center from 1990–2013 were reviewed. Factors associated with rates of locoregional control (LRC), distant metastasis (DM), disease-free survival (DFS), and overall survival (OS) were analyzed using the log rank test.
110 patients with FIGO stage II disease were identified. Most (84.5%) received EBRT±BT, with 13.6% receiving BT alone. With a median follow-up of 64.6months, the 5-year actuarial rates of LRC, DM, DFS, and OS were 94.9%, 85.1%, 67.9%, and 75.0%, respectively. With 5 locoregional failures, the only factor predictive of LRC was pelvic lymph node dissection. Characteristics associated with DM included age, LVSI, depth of myometrial invasion, and receipt of chemotherapy. Factors predictive of both DFS and OS were age, grade, adverse histology, LVSI, depth of myometrial invasion, and receipt of chemotherapy.
This represents the largest single-institution study for modern stage II endometrial cancer, confirming high rates of pelvic disease control after surgery and adjuvant therapy. With most patients receiving adjuvant radiotherapy, the predominant mode of failure, albeit low in absolute number, remains distant metastases.
•Modern stage II endometrial cancer is defined only by cervical stromal invasion.•Patients received surgical staging and adjuvant radiation with or without chemo.•Five-year rates of disease-free and overall survival were 68% and 75%.•The primary mode of disease recurrence was distant metastases.•Our data suggests recurrence risk may depend on radiation modality.
Metrics
Details
- Title
- Outcomes of stage II endometrial cancer: The UPMC Hillman Cancer Center experience
- Creators
- Katherine S. Chen - University of PittsburghHebist Berhane - UPMC Hillman Cancer CenterBeant S. Gill - UPMC Hillman Cancer CenterAlexander Olawaiye - Magee-Womens HospitalPaniti Sukumvanich - Magee-Womens HospitalJoseph L. Kelley - Magee-Womens HospitalMichelle M. Boisen - Magee-Womens HospitalMadeleine Courtney-Brooks - Magee-Womens HospitalJohn T. Comerci - Magee-Womens HospitalRobert Edwards - Magee-Womens HospitalJessica Berger - Magee-Womens HospitalSushil Beriwal - University of Pittsburgh
- Publication Details
- Gynecologic oncology, v 147(2), pp 315-319
- Publisher
- Elsevier
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Radiation Oncology (and Nuclear Medicine)
- Web of Science ID
- WOS:000415663600014
- Scopus ID
- 2-s2.0-85028618429
- Other Identifier
- 991021897277804721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Web of Science research areas
- Obstetrics & Gynecology
- Oncology